N/A N=26 Nourish Pilot & CoDesign Study
Nutrition, Healthy
Primary: Food Waste Volume — -796.19; 2308.38 grams
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Advanced Colorectal Carcinoma · Metastatic Colon Adenocarcinoma · Metastatic Rectal Adenocarcinoma
Primary: Median Progression Free Survival (PFS) — 7.9 months
N/A N=24 Training Grammar With Meaning
Language Disorders in Children
Primary: Change in the Use of Treated Grammatical Forms in Untreated Contexts — 6.6; 5.8 Generalization d
N/A N=18 Feasibility Study on the VERAFEYE System
Atrial Septal Defect · Atrial Fibrillation · Atrial Arrhythmia
Primary: Physician Feedback on VERAFEYE System — 100; 100; 100; 100 percentage of participants
N/A N=32 Developing Rectal USPE Measures for Suppositories (Project DRUM-S)
Microbicide Delivery System Perceptibility and Acceptability
Primary: User Perception Scale Scores — 3.31; 3.36; 2.12; 2.62 units on a scale
Phase 3 N=1,184 Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Infections, Meningococcal
Primary: Number of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1 — 156; 100; 39; 25 Participants
N/A N=21 Brain Network Modulation and Alcohol Use
Alcohol Use Disorder (AUD)
Primary: Neurofeedback Control — 0.061 correlation coefficient
N/A N=32 Study of the Aliviado DSD Caregiving Mastery Program
Delirium Superimposed on Dementia
Primary: Number of Participants Who Complete the Study — 26 Participants
Phase 2 N=12 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Any Advanced Solid Tumors · Triple Negative Breast Cancer · Non Small Cell Lung Cancer
Primary: Phase 1b: Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs), Serious AEs (SAEs), Trial Treatment-related TEAEs and Trial Treatment-related…
N/A N=144 Adolescent Inpatient Tobacco and ENDS Intervention
Vaping · Smoking
Primary: Self-reported 30-day Abstinence — 16; 25 Participants — p=0.91
N/A N=511 A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom
Contraception
Primary: 6 Month Pregnancy Probabilities With Typical Use — 0.5; 1.4; 4.0 percentage of probability
Phase 2 N=46 A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
Chronic Obstructive Pulmonary Disease
Primary: Change From Average Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) — 0.0525; 0.0393; 0.0115; -0.0287 Liters
Phase 3 N=378 A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea
Respiratory Syncytial Virus
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 12.4; 3.2; 11.6; 2.4 Percentage of participants
Phase 2 N=42 Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
Cystic Fibrosis
Primary: Parts A, B and D: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events — 3; 3; 3; 3 Participants
Phase 1 N=26 Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males
Healthy Men · Male Contraception · Healthy Women
Primary: Changes From Baseline (Cavg) for Serum Testosterone Levels in Females After Secondary Exposure to Nestorone + Testosterone Combination Gel — 22.84; 27.12; 29.12; 62.06…